Search
for
Sort by
Research
390-420 / 1000+ resultsresearch Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth
Blocking JAK-STAT signaling can lead to hair growth.
research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis
JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research JAK Inhibitors and Alopecia Areata
JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
research Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
research JAK-Inhibitors in Dermatology: Current Evidence and Future Applications
JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.
research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Emerging Drugs for Alopecia Areata: JAK Inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Efficacy of JAK 1/2 Inhibition in the Treatment of Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus
Baricitinib might help treat hair loss in lupus patients, but more research is needed.
research Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Under Development JAK Inhibitors for Dermatologic Diseases
New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Molecular Profiling of Frontal Fibrosing Alopecia Reveals TH1 and JAK-STAT Up-Regulation with No Suppression of Hair Keratins
Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
research An Open Label Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Clinical Investigation of JAK Inhibitor Tofacitinib in Scarring Alopecias
Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
research Janus Kinase (JAK) Inhibitors in Treating Alopecia Areata (AA)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research Scarring Alopecia Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Partial Restoration of Scalp Microbiota in Alopecia Areata with JAK Inhibitors
JAK inhibitors partially restore scalp bacteria balance in alopecia areata patients.
research Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.